E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 2, 1998, Pages 171-176

  Mann, Michael J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR E2F;

BLOOD VESSEL GRAFT; BLOOD VESSEL SHUNT; CONFERENCE PAPER; GENETIC ENGINEERING; PRIORITY JOURNAL;

EID: 0031948836     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.171     Document Type: Conference Paper

References (29)

1. CHANG, M.W., BARR, E., SELTZER, J. JIANG, Y.O., NABEL, G.J., NABEL, E.G., PARMACEK, M.S., and LEIDEN, J.M. (1995). Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267, 518-522.
2. CLOWES, A.W., and REIDY, M.A. (1991). Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia - A review. J. Vasc. Surg. 13, 885-891.
3. COX, J.L., CHAISSON, D.A., and GOTLEIB, A.I. (1991). Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis. Prog. Cardiovasc. Dis. 34, 45-68.
4. DEGREGORI, J., KOWALIK, T., and NEVINS, J.R. (1995). Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15, 4215-4224.
5. DEV, V., PARIKH, A., REN, M., GOLDENBERG, T., FISHBEIN, M.C., EIGLER, N., ROSSI, J., and LITVACK, F. (1995). Ribozymes to cell division cycle (CDC-2) kinase and proliferating cell nuclear antigen (PCNA) prevent intimal hyperplasia in rat carotide artery. Circulation 92(Suppl. I), I-634 (abstract).
6. FARIES, P.L., MARIN, M.L., VEITH, F.J., RAMIREZ, J.A., SUGGS, W.D., PARSONS, R.E., SANCHEZ, L.A., and LYON, R.T. (1996). Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J. Vasc. Surg. 24, 463-471.
7. FRANCIS, S.E., HUNTER, S., HOLT, C.M., GADSDON, P.A., ROGERS, S., DUFF, G.W., NEWBY, A.C., and ANGELINI, G.D. (1994). Release of platelet-drived growth factor activity from pig venous arterial grafts. J. Thorac. Cardiovasc. Surg. 108, 540-548.
8. GOLDMAN, S., COPELAN, J., MORITZ, T., HENDERSON, W., ZADINA, K., OVITT, T., et al. (1989). Saphenous vein graft patency 1 year after coronary artery bypass surgery and of antiplatelet therapy. Circulation 80, 1190-1197.
9. GRONDIN, C.M., CAMPEAU, L., THORNTON, J.C., ENGLE, J.C., CROSS, F.S., and SCHREIBER, H. (1989). Coronary artery bypass grafting with saphenous vein. Circulation 79, I-24-I-29.
10. HAMDAN, A.D., MISARE, B., CONTRERAS, M., LOGERFO, F.W., and QUIST, W.C. (1996). Evaluation of anastomotic hyperplasia progression using the cyclin specific antibody MTB-1. Am. J. Surg. 172, 168-170.
11. HOCH, J.R., STARK, V.K., and TURNIPSEED, W. (1995). The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J. Vasc. Surg. 22, 51-58.
12. INDOLFI, C., AVVEDIMENTO, E.V., RAPACCIUOLO, A., DI LORENZO, E., ESPOSITO, G., STABILE, E., FELICIELLO, A., MELE, E., GIULIANO, P., and CONDORELLI, G. (1995). Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med 1, 541-545.
13. MAJESKI, M.W., LINDNER, V., TWARDZIK, D.R., and REIDY, M.A. (1991). Production of transforming growth factor beta-1 during repair of arterial injury. J. Clin. Invest. 88, 904-910.
14. MANN, M.J., and DZAU, V.J. (1997). Gene Therapy of Cardiovascular Disease. (Excerpta Medica, Amsterdam).
15. MANN, M.J., GIBBONS, G.H., KERNOFFS, R.S., DIET, F.P., TSAO, P., COOKE, J.P., KANEDA, Y., and DZAU, V.J. (1995). Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. USA 92, 4502-4506.
16. MANN, M.J., GIBBONS, G.H., TSAO, P.S., VON DER LEYEN, H.E., BUITRAGO, R., KERNOFF, R., COOKE, J.P., and DZAU, V.J. (1997a). Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts. J. Clin. Invest. 99, 1295-1301.
17. MANN, M.J., KERNOFF, R., and DZAU, V.J. (1997b). Intra-operative transfection with E2F decoy oligonucleotide yields long-term resistance to vein graft atherosclerosis. J. Invest. Med. 45, 224A.
18. MANN, M.J., WHITTEMORE, A.D., DONALDSON, M.C., BELKIN, M.A., ORAV, E.J., POLAK, J., and DZAU, V.J. (1997c). Preliminary clinical experience with genetic engineering of human vein grafts: Evidence for target gene inhibition. Circulation 96, 14.
19. MORGAN, D.O. (1995). Principles of Cdk regulation. Nature 374, 131-134.
20. MORISHITA, R., GIBBONS, G.H., HORIUCHI, M., et al. (1995). A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 92, 5855-5859.
21. MORISHITA, R., GIBBONS, G.H., KANEDA, Y., and DZAU, V.J. (1994). Pharmacokinetics of antisense oligodeoxynucleotides (cyclin B1 and cdc2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149, 13-19.
22. 1 events and regulation of cell proliferation. Science 246, 603-608.
23. REIDY, M.A., FINGERLE, J., and LINDNER, V. (1992). Factors controlling the development of arterial lesions after injury. Circulation 86, III43-46.
24. SHI, Y., FARD, A., GALEO, A., HUTCHINSON, H.G., VERMANI, P., DODGE, G.R., HALL, D.J., SHAHEEN, F., and ZALEWSKI, A. (1994). Transcatheter delivery of c-myc antisense oligomers reduce neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90, 944-951.
25. SIMONS, M., EDELMAN, E.R., DEKEYSER, J.L., LANGER, R., and ROSENBERG, R.D. (1992). Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
26. WALKER, L.N., BOWEN-POPE, D.F., ROSS, R., and REIDY, M.A. (1986). Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc. Natl. Acad. Sci. USA 83, 7311-7315.
27. WEINBERG, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
28. WEINTRAUB, S.J., PRATER, C., and DEAN, D.C. (1992). Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358, 259-261.
29. ZWOLAK, R.M., ADAMS, M.C., and CLOWES, A.W. (1987). Kinetics of vein graft hyperplasia: Association with tangential stress. J. Vasc. Surg. 5, 126-136.